Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07512063 · ClinicalTrials.gov registry record
A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 480
- Enrollment target
NCT07512063: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07512063 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 480 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07512063 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 480 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated with a 1L cyclin dependent kinase 4/6 inhibitor (CDK4/6i) in the real-world setting.
Primary Outcome
Demographics included: * Age group * Sex * Race * Ethnicity * Geographical region * Payer type * Year of 1L treatment initiation * De novo or recurrent mBC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-03-17 |
What the finished NCT07512063 record still lists
NCT07512063 is an observational study that tracks outcomes without assigning an intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07512063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07512063 about?
NCT07512063 is a clinical study titled "A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors". The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated with a 1L cyclin dependent kinase 4/6 inhibitor (CDK4/6i) in the real-...
What is the current status of trial NCT07512063?
This trial is currently completed. The enrollment target is 480 participants. The study started on 2024-10-08. Estimated completion is 2025-03-17.
Who is sponsoring clinical trial NCT07512063?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI